Medmain

About Medmain

Medmain Inc. is a Japanese medical technology startup founded in 2018 by Osamu Iizuka. Iizuka, who serves as CEO, was inspired to enter the medical field after a long-term hospitalization at age 18. While in medical school at Kyushu University, he became interested in programming and, along with companions, began developing software to aid the medical field. The concept for Medmain emerged after a professor noted that a cell tracking system they developed could be applied to pathological diagnosis. The company's mission is to create a world where medical services can be accessed with technology anywhere, anytime. Medmain develops and provides "PidPort," an AI-powered cloud system designed to support digital pathology. This platform addresses the global shortage of pathologists and the resulting delays and regional disparities in pathological diagnosis. The company's business model is primarily B2B, serving medical institutions such as hospitals and research facilities. PidPort allows for the storage, management, viewing, and sharing of digital pathological specimen images on the cloud, eliminating the need for physical slide transportation and enabling remote diagnosis, consultations, and conferences. The system features a high-speed web viewer for comfortable image operation and can be accessed from a PC or tablet with an internet connection without requiring special software installation. A core feature of PidPort is its AI-driven analysis, which uses deep learning to provide highly accurate and rapid image analysis of tissues and cells for cancer screening. The AI models are developed through collaborative research with multiple medical institutions, using hundreds of thousands of pathological specimens to create the training data. The platform currently supports AI analysis for organs such as the stomach, colon, breast, lung, and pancreas, as well as cervical cells. By providing this technology, Medmain aims to reduce the workload and psychological burden on pathologists. The company generates revenue by providing its PidPort services, which range from creating virtual slides to offering diagnostic support, with customized plans available. As of May 2025, Medmain had raised a total of $19.6 million in funding and is using the capital to enhance product development, apply for regulatory approval, and expand internationally.